Outputs (60)

Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–2018 (2022)
Journal Article
West, J., Stilwell, P., Liu, H., Ban, L., Bythell, M., Card, T. R., Lanyon, P., Nanduri, V., Rankin, J., Bishton, M., & Crooks, C. J. (2022). Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–2018. HemaSphere, 6(11), Article e797. https://doi.org/10.1097/HS9.0000000000000797

Hemophagocytic lymphohistiocytosis (HLH) is rare, results in high mortality, and is increasingly being diagnosed. We aimed to quantify the incidence of diagnosed HLH and examine temporal trends in relation to age and associated diseases. Using nation... Read More about Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–2018.

Deuterium brain imaging at 7T during D2O dosing (2022)
Journal Article
Cocking, D., Damion, R. A., Franks, H., Jaconelli, M., Wilkinson, D., Brook, M., Auer, D. P., & Bowtell, R. (2023). Deuterium brain imaging at 7T during D2O dosing. Magnetic Resonance in Medicine, 89(4), 1514-1521. https://doi.org/10.1002/mrm.29539

Purpose
To characterize the (2H) deuterium MR signal measured from human brain at 7T in participants loading with D2O to ˜1.5% enrichment over a six-week period.

Methods
2H spectroscopy and imaging measurements were used to track the time-course... Read More about Deuterium brain imaging at 7T during D2O dosing.

The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development (2022)
Journal Article
Aljohani, A. I., Toss, M. S., Green, A. R., & Rakha, E. (2023). The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development. Breast Cancer Research and Treatment, 198, 423-435. https://doi.org/10.1007/s10549-022-06801-2

Background
Lymphovascular invasion (LVI) is regulated through complex molecular mechanisms. Cyclin B1 (CCNB1) was previously determined as being associated with LVI using large cohorts of breast cancer (BC) and artificial neural network (ANN) techni... Read More about The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development.

Management of secondary central nervous system lymphoma. (2022)
Journal Article
Cwynarski, K., Cummin, T., Osborne, W., Lewis, J., Chaganti, S., Smith, J., Linton, K., Greaves, P., McKay, P., Fox, C. P., & the British Society for Haematology (BSH) Committee. (2023). Management of secondary central nervous system lymphoma. British Journal of Haematology, 200(2), 160-169. https://doi.org/10.1111/bjh.18539

Biomolecular Condensation of the Human Papillomavirus E2 Master Regulator with p53: Implications in Viral Replication (2022)
Journal Article
Susana Borkosky, S., Fassolari, M., Campos-León, K., Hugo Rossi, A., Salgueiro, M., Antonela Pascuale, C., Peralta Martínez, R., Gaston, K., & de Prat Gay, G. (2022). Biomolecular Condensation of the Human Papillomavirus E2 Master Regulator with p53: Implications in Viral Replication. Journal of Molecular Biology, Article 167889. https://doi.org/10.1016/j.jmb.2022.167889

p53 exerts its tumour suppressor activity by modulating hundreds of genes and it can also repress viral replication. Such is the case of human papillomavirus (HPV) through targeting the E2 master regulator, but the biochemical mechanism is not known.... Read More about Biomolecular Condensation of the Human Papillomavirus E2 Master Regulator with p53: Implications in Viral Replication.

Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors (2022)
Presentation / Conference Contribution
Bishton, M., Crooks, C., Liu, H., Ban, L., Bythell, M., Card, T., Lanyon, P., Nanduri, V., Rankin, J., Stilwell, P., & West, J. Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors

Background: Haemophagocytic Lymphohistiocytosis (HLH) is a rare, life-threatening hyper-inflammatory syndrome triggered by constitutive and acquired risk factors including haematological malignancy, infection, auto-immunity and rheumatological diseas... Read More about Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors.

Factors Influencing 1-Year Survival in Haemphagocytic Lymphohistiocytosis: A National Cohort Study in England (2022)
Presentation / Conference Contribution
West, J., Stilwell, P., Liu, H., Ban, L., Bythell, M., Card, T., Lanyon, P., Nanduri, V., Rankin, J., Bishton, M., & Crooks, C. Factors Influencing 1-Year Survival in Haemphagocytic Lymphohistiocytosis: A National Cohort Study in England

Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe (2022)
Journal Article
Bishton, M. J., Salles, G., Golfier, C., Knauf, W., Bocchia, M., Turner, D., Slama, B., Harchowal, J., Marshall, S., Bosi, A., Lleonart, J. J. B., Welslau, M., Kim, S., Lee, Y. N., Zinzani, P. L., & Laribi, K. (2023). Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe. eJHaem, 4(1), 45-54. https://doi.org/10.1002/jha2.593

The rituximab biosimilar CT‐P10 is approved for the treatment of non‐Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT‐P10 and reference rituximab. However, real‐world data relating to treatment in patients with DLBC... Read More about Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe.

Histopathological impact of Redox-responsive methacrylamide based micellar nanoparticles on Orthotopic Models of Triple Negative Breast Cancers (2022)
Journal Article
Mehradnia, F., Moloney, C., Cavanagh, R., Pearce, A. K., Ritchie, A., Clarke, P., Rahman, R., Ibrahim, A., Grabowskab, A. M., & Alexander, C. (2022). Histopathological impact of Redox-responsive methacrylamide based micellar nanoparticles on Orthotopic Models of Triple Negative Breast Cancers. British Journal of Pharmacy, 7(2), https://doi.org/10.5920/bjpharm.1173

The therapeutic efficacy of anticancer nanocarriers ishighly dependent on their size, shape, targeting ability, and stimuli-responsiveness. Herein, we studied the in vivo therapeutic efficacy ofDoxorubicin (Dox) loaded redox responsive micellar-like... Read More about Histopathological impact of Redox-responsive methacrylamide based micellar nanoparticles on Orthotopic Models of Triple Negative Breast Cancers.

A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients (2022)
Journal Article
Xu, Q., Kaur, J., Wylie, D., Mittal, K., Li, H., Kolachina, R., Aleskandarany, M., Toss, M. S., Green, A. R., Yang, J., Yankeelov, T. E., Bhattarai, S., Janssen, E. A., Kong, J., Rakha, E. A., Kowalski, J., & Aneja, R. (2022). A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients. International Journal of Molecular Sciences, 23(21), Article 13322. https://doi.org/10.3390/ijms232113322

Extensive intratumoral heterogeneity (ITH) is believed to contribute to therapeutic failure and tumor recurrence, as treatment-resistant cell clones can survive and expand. However, little is known about ITH in triple-negative breast cancer (TNBC) be... Read More about A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients.